AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research Recipient
This award recognizes a worthy cancer researcher who has conducted highly meritorious laboratory, translational, or clinical cancer anywhere in the world at a relatively early state in his or her career.
Second Award Recipient
Pasi A. Janne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Director, Belfer Center for Applied Cancer Science
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Dr. Jänne will deliver his award lecture titled “Developing Combination Precision Therapies for Lung Cancer" at the AACR Annual Meeting 2018 in Chicago, IL. The award presentation and lecture were held Monday, April 16, 2018, at the McCormick Place North/South Convention Center.
The AACR established this award in recognition of Dr. Hong's extraordinary contributions to cancer research, cancer care, and cancer prevention during his brilliant career as a physician-scientist. This award recognizes a worthy cancer researcher who has conducted highly meritorious translational or clinical cancer research anywhere in the world at a relatively early stage in his/her career. It will honor the outstanding research of a young investigator who has not yet reached 51 years of age at the time of the award presentation.
Pasi A. Jänne, MD, PhD is recognized for pioneering research toward therapeutic discoveries, including being one of the co-discoverers of EGFR mutations. Findings from his work have led to the development of several clinical trials for patients with EGFR mutant lung cancer. This is coupled with the identification of drug resistance mechanisms, preclinical identification, and the study and clinical validation of mutant selective EGFR inhibitors. As a result, Dr. Jänne’s studies have helped define the current treatment paradigm for EGFR mutant lung cancer patients.
Dr. Jänne is the Director of the Lower Center for Thoracic Oncology at Dana Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana Farber Cancer Institute. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002 he earned a Masters Degree in clinical investigation from Harvard University.
Dr. Jänne has received multiple honors and awards for his research including, from Uniting Against Lung Cancer, American Lung Association, and the Bonnie J. Addario Lung Cancer Foundation. He is an elected member to the American Society of Clinical Investigation (2008), American Association of Physicians (2016) and the Finnish Academy of Science and Letters (2016). Dr. Jänne is also the recipient of 2010 American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award and one of the recipients for the 2010 AACR Team Science Award. In 2017, he was awarded an American Cancer Society Clinical Research Professorship.
2017: Roger S. Lo